Germany has reportedly scrapped a plan to introduce variable discount pricing for branded pharmaceuticals after strong pushback from drugmakers, according to Reuters. The initiative was part of a proposed healthcare reform package aimed at cutting drug spending, with Reuters citing an unnamed government source that the variable framework will be replaced by a fixed approach. The earlier plan would have required manufacturers to pay increased markdowns to German health insurers on list prices, on top of other cost-control measures. Industry leaders warned they could reduce investment, and some publicly discussed cuts tied to the reform. Eli Lilly and Boehringer Ingelheim said they would scale down planned spending by at least $1 billion, while Pfizer’s CEO Albert Bourla said the company was considering a similar pullback. The policy shift is a sign that German pricing mechanics can materially affect capital allocation decisions for global biopharma—and it mirrors international sensitivity to aggressive reimbursement reforms.